Pfizer Profits, Warns of Patent Lapses
417741
Pfizer Inc. PFE.N on Wednesday said  third-quarter earnings rose on higher sales of cholesterol and  arthritis drugs, but the company cautioned that 2005 results  will likely be hurt by generic competition for four other  popular medicines.
728273
Although a U.S. judge has halted  continued shipments of a generic form of Bristol-Myers Squibb  Co.'s  best-selling drug, analysts on Friday cautioned  that huge supplies already on the market would hurt the  company's earnings in 2006 and 2007.
437198
U.S. drugmaker Pfizer Inc  said on Wednesday a New York State court ruling related to litigation over the company's anti-inflammatory drug Celebrex may cause many cases to be dismissed.
140996
A day late and possibly several millions of dollars short. That's the scenario facing one drug manufacturer unless it can get a helping hand from Congress.
725823
NEW YORK/GROTON, Connecticut  - Pfizer Inc.  raised its 2006 profit forecast on Thursday and said its roster of experimental drugs in late-stage testing could triple by 2009, sending its shares higher.
259614
NEW YORK - Shares of pharmaceutical company Pfizer Inc. fell sharply in early trading after the firm reported an increased risk of heart disease for patients taking its Celebrex painkiller and arthritis drug.
238512
Shares of Pfizer Inc., the world's largest drugmaker, sank Monday on news that the company had halted development of a key new cholesterol treatment that was heralded as its engine for future growth as the company struggles with stagnant sales.
54894
U.S. stocks closed lower on Friday,  weighed down by a number of negative reports from top drug  makers, including Pfizer Inc. PFE.N, and a $2 jump in the  price of crude oil.
535194
Merck and Co. MRK.N suffered a  double blow on Friday when a court ruled that the patent on its  second-biggest drug will lapse a decade earlier than expected  and U.S. regulators elevated their probe of its withdrawn Vioxx  arthritis drug into a formal investigation.
560123
US stocks fell on Friday dragged down by a string of negative reports from drug makers, with Pfizer Inc. (PFE.N: Quote, Profile, Research) , AstraZeneca Plc.
543424
Pfizer Inc. reaffirmed its full-year guidance Wednesday despite a 48 percent drop in second-quarter profit because of lagging sales of cholesterol drug Lipitor and generic competition for Zoloft and Norvasc.
692639
Drugstore chain Rite Aid Corp.  on Tuesday warned that full-year profit and revenue would fall short of Wall Street expectations because of slowing pharmacy sales as companies try to curb health-care costs.
437095
Shares of Pfizer Inc. dropped 11% to $25.80 on Friday, after the company said a long-term study revealed that its Celebrex painkiller drug increased the risk of heart problems.
624082
Pfizer Inc., the world&#39;s largest drugmaker, said third-quarter earnings jumped 49 percent after merger-related expenses fell and sales of the cholesterol treatment Lipitor rose.
580189
U.S. drugmaker Pfizer Inc   said on Wednesday a New York State court ruling related to  litigation over the company's painkiller Celebrex may cause  many cases to be dismissed.
217275
In the cold, calculating world of Wall Street, that&#39;s how the unfolding drama of new test results on old drugs is playing out, as analysts see bright spots for Pfizer (PFE:NYSE - news - research) amid other drugs&#39; woes.
264090
NEW YORK - As Wall Street sifts through more than 300 third-quarter earnings reports this week, technology and pharmaceutical stocks will be getting some of the closest scrutiny.    The focus on drug companies results from a recent spate of bad news about Merck & Co...